undamentalytics Newsletter
Sign in

Krystal Biotech, Inc. balance sheet

At the end of fiscal 2025, Krystal Biotech, Inc. had total assets of $1.33bn, total liabilities of $114m and shareholders' equity of $1.22bn. It held $496m in cash against $0 of debt: net cash of $496m.

Balance sheet

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMSept 2026
Cash and equivalents341162358345496463
Receivables—042105127133
Inventory—07274051
Total current assets4423845887421,0251,122
Total assets6265588181,0561,3341,586
Accounts payable844537
Total current liabilities262933102103142
Total debt000000
Total liabilities333640109114150
Shareholders' equity5945227799461,2201,436
Net debt (negative = net cash)−341−162−358−345−496−463
Shares outstanding25m26m28m29m29m30m

Balances at each fiscal year end (quarter end in the quarterly view). Total debt is short- plus long-term borrowings, including lease debt where the company reports it within debt. Where assets do not equal liabilities plus shareholders' equity, the difference (non-controlling interests, redeemable preferred shares) is shown on its own line.

Compare with peers

Head to head: ARQT vs KRYSCRMD vs KRYSARDX vs KRYSADMA vs KRYS

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Krystal Biotech, Inc.'s SEC filings (10-K and 10-Q), retrieved November 2, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Krystal Biotech, Inc.